Our Anti-FGL1 monoclonal antibody program aims to develop therapeutic monoclonal antibodies that could recognize and potentially, target against FGL1 (Fibrinogen-like Protein 1). The highlight feature of this program, FGL1, was only identified in 2019. We believe our program will be fairly unique and is a leading program in current bio-pharmaceutical market.
FGL-1 belongs to fibrinogen family since it’s structurally related to fibrinogen. And in late 2019, FGL-1 was identified as a major immune inhibitory ligand of Lymphocyte Activation Gene 3 protein (LAG-3, see Fig.1).
Fig.1 Mechanism of action for FGL1-LAG3 in T cell suppression.1
• In NSCLC and Melanoma, high level of FGL1 is related with poor prognosis/survival rate..
Fig.2 High level of FGL1 is related with poor prognosis/survival rate.1
• The expression value of FGL1 is significantly higher, compared to normal tissue, among various type of cancer.
Fig.3 The expression value of FGL1 is significantly higher among various type of cancer.1
• Treatment with anti-FGL1 antibody shows higher survival rate compared to the control group, and the efficacy of anti-FGL1 plus anti-B7-H1 therapy is better in other treatments. These findings may indicate that anti-FGL1 has anti-tumor efficacy.
Fig.4 The anti-tumor efficacy of anti-FGL1 antibody.1
Lung cancer, characterized by uncontrolled cell growth in lung tissues, is the most common type of cancer for several decades. About 80% to 85% lung cancers are non-small cell lung cancer (NSCLC). To date, several therapeutic antibodies on market can be used to treat NSCLC. And scientists are trying to find more therapeutic targets with a better anti-tumor efficacy.
• Based on Cancer Statistics, 2017, lung cancer is the second most common cancer in the United States and is one of the leading causes of cancer death.
• Preliminary Data of Anti-FGL1 Efficacy to Treat NSCLC
• FGL1 is highly expressed in patients with NSCLC (left), and high level FGL1 in NSCLC is related with poor prognosis(right).
Fig.5 The expression level of FGL1 in NSCLC.1
• Treatment with anti-FGL1 shows better anti-NSCLC efficacy, especially when used in combination with anti-B7-H1.
Fig.6 Efficacy of the combination of anti-FGL1 and anti-B7-H1.1
• There are NO clinical trials examining FGL1 as the target. Our program will be a pioneer in this field.
• FGL1 is a novel target among all the other immune checkpoint inhibitors. It is believed to be a shining star and the next marketing prospect in the field. From our standpoint, since the combination efficacy with anti-B7-H1 (PD-L1) is more promising as shown by the preliminary data, our therapeutic anti-FGL1 discovery will focus on combination therapy with anti-B7-H1 (PD-L1).
We have extensive experience in performing comprehensive program development and problem-solving. For our Next-IOTMprograms, we are committed to delivering the completed program to our partners within 1.5 year. The exact timetable will be determined on a case by case basis. Here is a simple draft timeline for quick browsing.
Fig.7 The timeline of Next-IO™ programs.
Creative Biolabs is looking for potential partners and gain collaboration opportunities to develop anti-FGL1 antibody program. We have strategic and trusted partnerships with many partners all over the world. For years, we are dedicated to helping our partners get IND approval from the FDA.
If you are interested in our program, please feel free to contact us for more details.
For Research Use Only | Not For Clinical Use
Download our brochure